Skip to main content
Top
Published in: Familial Cancer 1/2016

01-01-2016 | Short Communication

Rhabdoid tumor predisposition syndrome caused by SMARCB1 constitutional deletion: prenatal detection of new case of recurrence in siblings due to gonadal mosaicism

Authors: Laura Gigante, Irene Paganini, Marina Frontali, Serena Ciabattoni, Federica Carla Sangiuolo, Laura Papi

Published in: Familial Cancer | Issue 1/2016

Login to get access

Abstract

Rhabdoid tumors are aggressive malignancies that show loss-of-function mutations of SMARCB1 gene, a member of the SWI/SNF chromatin-remodeling complex controlling gene transcription. One-third of patients affected by rhabdoid tumor harbor a germ-line mutation of SMARCB1 defining a rhabdoid tumor predisposition syndrome. The occurrence of a second somatic mutation determines the development of neoplasia in a two-hit model. Most germ-line mutations occur de novo, and few cases of recurrence in a sibship have been described. Here we report on a new Italian family with recurrence of SMARCB1 germ-line deletion in two siblings due to gonadal mosaicism. The deletion was identified in the 9-month-old proband with malignant rhabdoid tumor of the right kidney and disseminated metastases. Testing of both parents confirmed the de novo origin of the mutation, but recurrence was then detected prenatally in a new pregnancy. This is the sixth family with malignant rhabdoid tumor predisposition syndrome with the recurrence of the same germ-line SMARCB1 mutation in the sibship but not in healthy parents, suggesting that gonadal mosaicism is a less rare event than supposed. The clinical outcome in our patient confirms previous data of poorer outcome in patients with rhabdoid tumor predisposition syndrome.
Literature
1.
go back to reference Biegel JA, Zhou JY, Rorke LB et al (1999) Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59:74–79PubMed Biegel JA, Zhou JY, Rorke LB et al (1999) Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59:74–79PubMed
4.
go back to reference Louis DN, Deutsches Krebsforschungszentrum Heidelberg, International Agency for Research on Cancer, World Health Organization (2007) Rhabdoid tumour predisposition syndrome. WHO classification of tumours of the central nervous system. WHO Press, World Health Organization Louis DN, Deutsches Krebsforschungszentrum Heidelberg, International Agency for Research on Cancer, World Health Organization (2007) Rhabdoid tumour predisposition syndrome. WHO classification of tumours of the central nervous system. WHO Press, World Health Organization
9.
go back to reference Rousseau-Merck MF, Versteege I, Legrand I et al (1999) hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. Cancer Res 59:3152–3156PubMed Rousseau-Merck MF, Versteege I, Legrand I et al (1999) hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. Cancer Res 59:3152–3156PubMed
10.
go back to reference Kordes U, Bartelheim K, Modena P et al (2014) Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS). Pediatr Blood Cancer 61:919–921. doi:10.1002/pbc.24793 PubMedCrossRef Kordes U, Bartelheim K, Modena P et al (2014) Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS). Pediatr Blood Cancer 61:919–921. doi:10.​1002/​pbc.​24793 PubMedCrossRef
11.
go back to reference Kordes U, Gesk S, Frühwald MC et al (2010) Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. Genes Chromosomes Cancer 49:176–181. doi:10.1002/gcc.20729 PubMed Kordes U, Gesk S, Frühwald MC et al (2010) Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. Genes Chromosomes Cancer 49:176–181. doi:10.​1002/​gcc.​20729 PubMed
Metadata
Title
Rhabdoid tumor predisposition syndrome caused by SMARCB1 constitutional deletion: prenatal detection of new case of recurrence in siblings due to gonadal mosaicism
Authors
Laura Gigante
Irene Paganini
Marina Frontali
Serena Ciabattoni
Federica Carla Sangiuolo
Laura Papi
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2016
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-015-9836-6

Other articles of this Issue 1/2016

Familial Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine